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ABSTRACT
Introduction: Numerous intrinsic and extrinsic
factors have been associated with the pathophysi-
ology of rosacea, including dysregulation of innate
immunity. A high level of cathelicidin antimicro-
bial peptides (e.g., LL-37) has been shown in the
facial skin of patients with rosacea. Excessive pro-
duction of both LL-37 and KLK5, the serine pro-
tease responsible for its cleavage, has been
suggested to play a role in the pathophysiology of
rosacea. Ivermectin 10 mg/g cream, indicated for
the treatmentof inflammatory lesionsof rosacea, is
reported to have dual anti-parasitic and anti-in-
flammatory properties. However, the exact mech-
anism of action of ivermectin cream in the
treatment of rosacea is unknown.
Methods: This study aimed to evaluate the effect
of ivermectin on the expression of KLK5 and the
subsequent effect on the maturation process of
cathelicidins. Experimental studies were per-
formed either on normal human epidermal ker-
atinocytes (NHEK), reconstructed human
epidermis (RHE) or on human skin ex vivo stim-
ulated with calcitriol (1a,25-dihydroxyvitamin
D3), which is known to induce KLK5 and LL-37
expression.
Results: The results show that ivermectin is
able to inhibit KLK5 and CAMP gene expression
and protein secretion in NHEK cells stimulated
with calcitriol. Those results were confirmed in
3D models of the skin (RHE and skin ex vivo).
The anti-inflammatory effects of ivermectin
were associated with an inhibition of IL-8, IL-6
and MCP-1 (CCL2) secretion from NHEK cells.
Conclusions: These results suggest that iver-
mectin can prevent the inflammatory effects of
rosacea triggered by abnormal LL-37 processing,
through the inhibition of KLK5 gene expression
in the epidermis.
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INTRODUCTION
Rosacea is an inflammatory disease of the facial
skin, characterized by a variety of visible mani-
festations including erythema, papules, pus-
tules and telangiectasias [1, 2]. The
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pathophysiology of rosacea is yet to be fully
elucidated; however, current evidence suggests
that rosacea-prone skin inherently displays
dysregulation of the neurovascular/neuroim-
mune system and the innate immune system
[3–5]. The dysregulation of the innate immune
system is supported by an augmentation of the
cathelicidin innate immunity pathway [5–9].
Patients with rosacea express increased levels
of cathelicidin (LL-37) in their facial skin com-
pared with normal skin [10]. LL-37 is an
antimicrobial peptide that provides innate
defense against microbial organisms, and has
been shown to promote cellular inflammation,
as well as increased vascularity and angiogenesis
[11, 12]. The elevated levels of LL-37 observed in
patients with rosacea are thought to result from
unusually high levels of the serine protease
kallikrein-5 (KLK5) [6, 10]. KLK5 is responsible
for the cleavage of the inactive precursor pro-
tein hCAP18 in the epidermis to form the active
antimicrobial peptide LL-37 [6, 10]. LL-37 pep-
tide fragments have been shown to control
expression of extracellular matrix components,
angiogenesis and leukocyte chemotaxis [11, 12].
Injection of these peptide fragments into the
skin of mice led to an inflammatory phenotype
similar to that seen in patients with rosacea
[10]. Therefore, agents inhibiting the produc-
tion of KLK5 or blocking its activity could pre-
vent the expression of LL-37. This, in turn,
could have inhibitory effects on the inflamma-
tory cascade associated with rosacea [5].
Agents used in the treatment of rosacea, such
as doxycycline, azelaic acid and metronidazole,
have been shown to act on different targets
within the inflammatory pathway [13]. The
mechanism of action of two of these therapeu-
tic agents has been linked to the inhibition of
KLK5 [14, 15]. Oral doxycycline indirectly
inhibits serine protease activity by inhibiting
the matrix metalloproteinases involved in the
activation of KLK5 [14]. Adults with papulo-
pustular rosacea (PPR) were treated with doxy-
cycline 40-mg modified-release capsules once
daily for 12 weeks. LL-37 levels decreased over
the course of 12 weeks of doxycycline treat-
ment, and low levels of protease activity and
LL-37 expression at 12 weeks correlated with
clinical success [16]. Azelaic acid, a topical
treatment for PPR, has been shown to directly
inhibit KLK5 expression [15]. Nine-day treat-
ment of mouse skin with azelaic acid 150 mg/g
significantly decreased KLK5 messenger RNA
(mRNA) expression compared with skin treated
with vehicle control [15]. Adults with PPR who
applied azelaic acid 150 mg/g twice daily
showed significantly decreased CAMP (the gene
encoding cathelicidin) mRNA after 4 weeks and
decreased KLK5 mRNA after 12 weeks [15].
The exact mechanism of action of ivermectin
cream 10 mg/g, a new agent indicated for the
treatment of inflammatory lesions of rosacea,
remains unclear. However, it has been reported
that ivermectin has both anti-inflammatory and
anti-parasitic properties [17]. Ivermectin binds
with high affinity to glutamate-gated chloride
channels (commonly found in invertebrate
nerve and muscle cells), resulting in hyperpo-
larization of the cells. This results in paralysis
and death of parasites [17]. Importantly, iver-
mectin does not have this effect in human cells.
Ivermectin also has anti-inflammatory effects; it
has been shown to decrease humoral and cel-
lular immune responses including neutrophil
chemotaxis [18]. In order to further elucidate
the mechanism of action of ivermectin and the
inflammatory pathways that it targets, this
study investigated the effect of ivermectin on
the protein and gene expression of KLK5, LL-37
and pro-inflammatory markers including inter-
leukin (IL)-8, IL-6 and monocyte chemoattrac-
tant protein (MCP)-1 [also known as chemokine
(C–C motif) ligand (CCL) 2].
METHODS
Normal Human Epidermal Keratinocytes
Normal human epidermal keratinocytes
(NHEKs) were isolated from abdominal plastic
surgery at Nestle´ Skin Health R&D (Sophia
Antipolis, France) as previously described
[19–21] and cultured in Minimum Essential
Media (MEM; Gibco, ThermoFisher Scientific,
Waltham, MA, USA) medium supplemented
with 10% foetal bovine serum (FBS; Gibco),
10 ng/ml epidermal growth factor (Bec-
ton–Dickinson, Franklin Lakes, NJ, USA),
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0.4 lg/ml of hydrocortisone,1.8 9 10-4 M ade-
nine, 5 lg/ml insulin, 5 lg/ml transferrin, 2 pM
tri-iodothyronin and 0.1 lg/ml cholera toxin
(all from Sigma Aldrich, St. Louis, MO, USA), in
an incubator at 37 C, 5% CO2, and saturated
humidity. At sub-confluence, cells were disso-
ciated with tryspin-ethylenediaminetetraacetic
acid (Gibco) and frozen in liquid nitrogen at
4 9 106 cells/vial in MEM growth medium sup-
plemented with 10% dimethyl sulfoxide
(DMSO) 20% FBS. For the experiment (n = 6
replicates/condition), NHEK cells were seeded at
10,000 cells/cm2 in 48-well culture plates in
KGM-Gold medium (Lonza, Basel, Switzerland)
with growth supplements. At confluence, media
were removed from cells and replaced with
media containing compounds at the indicated
concentration during overnight incubation
before stimulation either with calcitriol
(1a,25-dihydroxyvitamin D3; Sigma Aldrich) or
LL-37 (Invivogen, San Diego, CA, USA). All
treatments and stimulations were done in
KGM-Gold medium (Lonza) with growth sup-
plements. Cells were allowed to incubate for up
to 48 h. Media were collected after 24 and 48 h
of stimulation and stored at -20 C until anal-
ysis. Before gene expression analysis, cells were
lysed using lysis buffer from Agencourt RNA
advance Tissue Kit (Beckman Coulter, Bria, CA,
USA) and stored at -20 C until ribonucleic acid
(RNA) extraction.
Reconstructed Human Epidermis
Reconstructed human epidermis models (RHE;
EpiSkin, L’Ore´al, Lyon, France) 0.33 cm2/HTS
were purchased at D17 from Episkin (L’Ore´al,
Lyon, France). At reception, RHE D18 were
removed from the agarose–nutrient solution in
the multiwell plate and immediately placed in a
plate in which each well had previously been
filled with SkinEthic Growth Medium (EpiSkin,
L’Ore´al, Lyon, France) at room temperature.
Culture dishes were placed in the incubator at
37 C, 5% CO2 and saturated humidity. Testing
could be initiated after at least 2 h resting. For
the experiment (n = 5 replicates/condition),
topical treatment with study compounds was
applied to RHE D18 at 1 ll/0.1 cm2. After
overnight incubation, a second treatment with
the same compound was applied 1 h before RHE
stimulation with topical calcitriol (1a,25-dihy-
droxyvitamin D3; Sigma). RHE were allowed to
incubate for up to 24 h. Media was collected
after 24 h and stored at -20 C until analysis.
Before gene expression analysis, RHE samples
were lysed using lysis buffer from Agencourt
RNA advance Tissue Kit (Beckman Coulter) and
stored at -20 C until RNA extraction.
Skin Ex Vivo
Healthy human skin samples received at Nestle´
Skin Health R&D are derived from abdomino-
plasty surgery and obtained with the patient’s
consent and with local IRP approval. Skin
biopsies were performed using 8-mm biopsy
punches and placed on Transwell cell culture
inserts, 24 mm diameter with a 8-lm polycar-
bonate membrane (Costar; Sigma Aldrich) in
6-well plates containing KGM-Gold medium
(Lonza) with growth supplements. For the
experiment (n = 3 replicates/condition), surgi-
cal steel rings were deposited on the surface of
the skin to allow topical treatment. Compounds
were applied on skin ex vivo at 1 ll/0.1 cm2.
After overnight incubation, a second treatment
with the same compound was applied 1 h
before skin stimulation either by topical treat-
ment with calcitriol (1a,25-dihydroxyvitamin
D3; Sigma Aldrich) or with LL-37 (Invivogen).
Biopsies were allowed to incubate for up to 72 h.
In order to proceed to histologic analysis on
each replicate of treatment, a biopsy of 4 mm in
diameter was performed inside the surgical steel
rings. The sample was then tape-stripped ten
times using D-squames discs (Monaderm,
Monaco) and stored in 2-mL microtubes at
-80 C until protein analysis. Following
tape-stripping, further 4-mm biopsies were car-
ried out in order to perform gene expression
and protein analysis.
Gene Expression
Cells were lysed using lysis buffer, and then
stored at -20 C until total RNA extraction was
performed with the Agencourt RNA advance
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Tissue Kit (Beckman Coulter). RHE and skin
biopsies were lysed in Tissue grinding
CKMix50-R containing 600 lL of lysis buffer
and using Precellys-Dual (Ozyme, Mon-
tigny-le-Bretonneux, France). Reverse tran-
scription was performed from 100 ng of total
RNA using the High Capacity Reverse tran-
scription kit (High Capacity RNA-to-cDNATM
Kit; Applied Biosystems, Foster City, CA, USA).
Pre-developed Taqman Assay probes were used
to analyze gene expression on the Quantstudio
12 K Flex System (Applied Biosystems). Fold
modulation relative to the control sample and
adjusted P value (False Discovery Rate Ben-
jamini and Hochberg; FDR_BH) were calculated
using the Array Studio software. ‘‘Undeter-
mined’’ cycle threshold (Ct) values were arbi-
trarily fixed at 40 to perform the analysis.
Results were considered significant when at
least a twofold difference in expression level was
detected and statistical analysis revealed an
adjusted P value (FDR_BH)\0.05.
Proteins Dosage
Total protein was extracted from D-squames
using 400 lL Cell Lysis Buffer (Cell Signaling
Technology, Danvers, MA, USA) in 2-mL
Eppendorf microtubes. RHE and skin biopsies
were lysed in Tissue grinding CKMix50-R con-
taining 600 lL of Cell Lysis Buffer (Cell Signal-
ing Technology) and using Precellys-Dual
(Ozyme, Montigny-le-Bretonneux, France).
Total protein extract from RHE, skin biopsies
and D-squames were quantified by a protein
assay based on the Bradford method (Bio-Rad,
Hercules, CA, USA). KLK5 protein (Human Kal-
likrein 5 Quantikine ELISA Kit; R&D Systems,
Minnneapolis, MN, USA), Cathepsin C (Anti-
bodies-online, Atlanta, GA, USA) and LL-37
(Hycult biotech, Uden, The Netherlands) in
NHEK culture media, RHE culture media and in
skin ex vivo biopsies were measured by ELISA
according to the manufacturer recommenda-
tion. Interleukin 8 (IL-8) secretion was quanti-
fied by HTRF (Human IL-8 Assay Kit; CisBio
Assay, Codolet, France), according to the man-
ufacturer’s recommendations. ProcartaPlex
Multiplex Luminex Immunoassays
(eBioscience, Affymetrix, Santa Clara, CA, USA)
was used to enable simultaneous detection of 11
analytes in one sample. The analytes were
glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), chemokine (C–X–C motif) ligand
(CXCL) 1, IL-6, CXCL10, CXCL11, chemokine
(C–C motif) ligand (CCL) 2, CXCL9, CCL20,
CCL5, soluble intercellular adhesion molecule
(sICAM)-1, and tumur necrosis factor (TNF)-a.
Immunohistochemistry
Tissues, either reconstructed epidermis or
biopsies, were placed in fixative to preserve
basic tissue architecture; they were then
embedded in paraffin to support the tissue.
Sections of 5 lm were then cut and placed on a
microscope slide for staining. Hema-
toxylin-eosin staining was performed on Sym-
phony automate (Roche, Basel, Switzerland).
Immunohistochemistry was performed on Dis-
covery Xt, Ventana (Roche) using a rabbit
anti-KLK5 antibody (TA321822; OriGene Tech-
nologies, Rockville, MD, USA) and a mouse
anti-LL-37 antibody (sc-166770 clone D-5; Santa
Cruz Biotechnology, Dallas, TX, USA).
Compounds
Calcitriol (1a,25-dihydroxyvitamin D3) was
purchased from Sigma Aldrich, and LL-37 from
Invivogen and used following suppliers’ rec-
ommendations. Ivermectin, azelaic acid and
metronidazole were supplied by the chemical
library management unit of Nestle´ Skin Health
R&D. For systemic treatment, compounds were
dissolved in DMSO at the desired concentra-
tions, while 100% ethanol was used as vehicle
for topical treatment.
Statistical Analysis
Statistical analysis was performed using bilateral
and homoscedastic Student’s t test, and P\0.05
was considered to be statistically significant.




Effect of Ivermectin on Expression
of KLK5 and the LL-37 Precursor Protein
hCAP18
To observe the effect of ivermectin on KLK5
secretion, the human epidermal cells were
incubated overnight in media containing 1 lM
ivermectin, azelaic acid or metronidazole before
being stimulated with calcitriol (Fig. 1a). In
order to simulate the upregulation of KLK5 and
LL-37 observed in the skin of patients with
rosacea, NHEK cells were treated with 100 nM
calcitriol (the hormonally active metabolite of
vitamin D) as previously described [22]. The
Fig. 1 Ivermectin treatment inhibits KLK5 secretion from
human epidermal cells. a NHEK cells were pre-treated
with ivermectin, azelaic acid, metronidazole at 1 lM or
vehicle control overnight before 48 h stimulation with
100 nM calcitriol. KLK5 release was measured by ELISA.
Data show mean ± SD from 3 independent experiments.
b RHE was pre-treated with ivermectin, azelaic acid,
metronidazole at 1% w/v or vehicle control (100%
ethanol) overnight before 24 h topical stimulation with
10 lM calcitriol. KLK5 release was measured by ELISA.
Data show mean ± SD from two independent experi-
ments. c Ex vivo skin biopsies were pre-treated with
ivermectin, azelaic acid, metronidazole at 1% w/v or
vehicle control overnight before 48 h topical stimulation
with 10 lM calcitriol. KLK5 release was measured by
ELISA. Data show mean ± SD from two independent
experiments. NS not signiﬁcant. **P\ .01, ***P\ .001,
Student’s t test. d Immunohistologic staining of paraf-
ﬁn-embedded reconstructed epidermis using anti-KLK5
antibody. Top panel RHE was pre-treated with vehicle
control overnight and then was stimulated with vehicle
control. Middle panel RHE was pre-treated with vehicle
control overnight before being stimulated topically with
10 lM calcitriol. Lower panel RHE was pre-treated with
ivermectin at 1% w/v overnight before being stimulated
topically with 10 lM calcitriol. The epidermis was then
parafﬁn-embedded and stained with anti-KLK5 antibody
(in red). Scale bars 100 lm
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supernatant was collected 48 h later and ana-
lyzed by ELISA for the presence of KLK5. No
toxicity has been observed with compounds at
the concentration tested (data not shown).
Pre-treatment with ivermectin resulted in a
significant decrease in the concentration of
KLK5 secreted from NHEK cells (P\0.001;
Fig. 1a) compared with vehicle control (DMSO).
However, no significant difference was observed
when NHEK cells were treated with azelaic acid
or metronidazole (Fig. 1a).
This experiment was then repeated using
topical ivermectin on RHE, which is the clini-
cally relevant application method. Ivermectin
1% w/v was applied to a RHE layer and left to
incubate overnight. A second treatment was
given 1 h before RHE stimulation with 10 lM
calcitriol. The supernatant was collected 24 h
later and analyzed by ELISA for the presence of
KLK5. Treatment with topical ivermectin resul-
ted in a significant decrease in the concentra-
tion of KLK5 secreted from RHE cells (P\0.001)
compared with vehicle control (ethanol;
Fig. 1b). Similarly, two treatments with topical
ivermectin significantly decreased the amount
of KLK5 secreted from ex vivo human skin
biopsies after stimulation with calcitriol
(P = 0.006) compared with vehicle control
(Fig. 1c, Supplementary Fig. 1). Histologic anal-
ysis (data not shown) has been performed in
order to ensure that ivermectin did not affect
the integrity of ex vivo human skin biopsies. No
significant difference in KLK5 secretion was
observed after topical treatment with azelaic
acid or metronidazole (Fig. 1c).
To confirm these results, immunohistologic
staining of paraffin-embedded reconstructed
epidermis was carried out. Analysis of KLK5
expression by the differentiated keratinocytes
showed an increase in KLK5 after stimulation
with calcitriol, which was substantially inhib-
ited by pre-treatment with topical ivermectin
(Fig. 1d, qualitative assessment). This indicates
that ivermectin significantly inhibits the intra-
cellular expression and secretion of KLK5 from
keratinocytes, both in vitro and ex vivo. As
previously mentioned, KLK5 is responsible for
the cleavage of the inactive precursor protein
hCAP18 in the epidermis to form the active
antimicrobial peptide LL-37 [6, 10].
In order to assess whether ivermectin has an
effect on the expression of hCAP18 in ker-
atinocytes, the cells were incubated overnight
in media containing 1 lM ivermectin, azelaic
acid or metronidazole before being stimulated
with calcitriol. The supernatant was collected
48 h later and analyzed by ELISA for the pres-
ence of hCAP18. Pre-treatment with ivermectin
resulted in a decrease in the concentration of
hCAP18 secreted from NHEK cells compared
with vehicle control (DMSO), but this difference
was not statistically significant (Fig. 2a). This
decrease can be observed more dramatically by
immunohistologic analysis of hCAP18/LL-37
expression in RHE cells (Fig. 2b, qualitative
assessment). Calcitriol stimulation substantially
increases the level of hCAP18 staining (indi-
cated by black arrows) observed in the differ-
entiated keratinocytes compared to vehicle
control. Pre-treatment with ivermectin resulted
in an inhibition of hCAP18/LL-37 protein
expression, resulting in staining that is compa-
rable to vehicle control (Fig. 3b). Taken toge-
ther, these results indicate that pre-treatment
with ivermectin inhibits the expression of KLK5
and the LL-37 precursor protein hCAP18.
Effect of Ivermectin on Cytokine Secretion
Ivermectin has been previously shown to inhi-
bit multiple pro-inflammatory cytokines which
are downstream of LL-37 activation, including
IL-6 and TNF-a [23]. However, the effect of
ivermectin on IL-8, the pro-inflammatory cyto-
kine responsible for neutrophil recruitment
[24, 25], has yet to be elucidated. Here, we
pre-treated NHEK cells with ivermectin, azelaic
acid, metronidazole or vehicle control before
stimulating them with calcitriol, and then
measured IL-8 secretion after 48 h. Ivermectin
significantly reduced IL-8 response at 48 h
compared with vehicle control (P\0.001;
Fig. 3a). This inhibition of IL-8 secretion was
not observed after pre-treatment with azelaic
acid or metronidazole. These results were con-
firmed in 3D models of the skin, where RHE and
ex vivo skin biopsies were pre-treated with
topical ivermectin or vehicle control and then
stimulated with calcitriol (Fig. 3b, c).
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Stimulation of keratinocytes with LL-37 has
been shown to induce keratinocyte migration,
proliferation and production of pro-inflamma-
tory cytokines [26]. Therefore, we evaluated the
effect of ivermectin on secretion of IL-8 after
stimulation with LL-37. Ivermectin significantly
decreased the secretion of IL-8 from NHEK cells
compared with vehicle control after stimulation
with LL-37 (Fig. 3d). However, pre-treatment
with azelaic acid or metronidazole had no effect
on IL-8 secretion. Overall, these results suggest
that pre-treatment with ivermectin inhibits the
secretion of IL-8 after stimulation with both
calcitriol and LL-37.
Fig. 2 Ivermectin treatment inhibits LL-37 expression in
human epidermal cells. a NHEK cells were pre-treated
with vehicle control (100% ethanol) or 1 lM ivermectin,
azelaic acid or metronidazole overnight before 48 h
stimulation with 100 nM calcitriol. hCAP18/LL-37
release was measured by ELISA. Data show mean ± SD
from two independent replicates. NS not signiﬁcant.
***P\ .001, Student’s t test. b Immunohistologic staining
of parafﬁn-embedded reconstructed epidermis using
anti-LL-37 antibody (in red). Top panel RHE was
pre-treated with vehicle control overnight and then was
stimulated with vehicle control. Middle panel RHE was
pre-treated with vehicle control overnight before being
stimulated topically with 10 lM calcitriol. Lower panel
RHE was pre-treated with ivermectin overnight before
being stimulated with calcitriol. The epidermis was then
parafﬁn-embedded and stained with anti-LL-37 antibody
(in red). Scale bars 100 lm
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To assess the effect of ivermectin on other
cytokines present in the skin, multiplex
immunoassays were carried out on ex vivo skin
biopsies. Only the levels of IL-6, CCL2, CXCL10
and soluble ICAM-1 were sufficient to be
quantifiable in the assays. The results show that
ivermectin significantly inhibits the secretion of
IL-6 and CCL2 (Supplementary Fig. 2). Taken
together, these results indicate that ivermectin
significantly inhibits the signaling pathway
downstream of cathelicidin.
Effect of Ivermectin on Gene Expression
of KLK5 and Cathelicidin
It has been previously shown that treatment
with azelaic acid directly affects the gene
expression of KLK5 and cathelicidin [15]. It is
therefore possible that the inhibition of KLK5,
LL-37 and IL-8 protein expression reported in
this study could be due to a direct effect on
KLK5 and CAMP gene expression. In order to
verify this hypothesis, we evaluated whether
Fig. 3 Ivermectin treatment inhibits IL-8 secretion from
human epidermal cells. a NHEK cells were pre-treated
with vehicle control (100% ethanol) or 1 lM ivermectin,
azelaic acid or metronidazole overnight before 48 h
stimulation with 100 nM calcitriol. IL-8 release was
measured by HTRF. Data show mean ± SD from 6
independent replicates. b RHE was pre-treated with
ivermectin, azelaic acid, metronidazole at 1% w/v or
vehicle control overnight before 24 h topical stimulation
with 10 lM calcitriol. IL-8 release was measured by
HTRF. Data show mean ± SD from two independent
experiments. c Ex vivo skin biopsies were pre-treated with
ivermectin, azelaic acid, metronidazole at 1% w/v or
vehicle control overnight before 48 h topical stimulation
with 10 lM calcitriol. IL-8 release was measured by
HTRF. Data show mean ± SD from two independent
experiments. d NHEK cells were pre-treated with iver-
mectin, azelaic acid, metronidazole or vehicle control
overnight before 24 h stimulation with LL-37 25 lg/ml.
IL-8 release was measured by HTRF. Data show
mean ± SD from two independent experiments. NS not
signiﬁcant. **P\ .01, ***P\ .001, Student’s t test
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ivermectin inhibits KLK5, LL-37 and IL-8 mRNA
expression after stimulation with calcitriol.
Human ex vivo skin biopsies were pre-treated
with topical ivermectin or ethanol as vehicle
control and then stimulated with calcitriol for
either 24 or 72 h. Topical treatment with iver-
mectin significantly and selectively inhibits
CAMP gene expression induced by 24-h stimu-
lation with calcitriol. No other genes encoding
markers of inflammation were affected by the
treatment with ivermectin. The effect on KLK5
gene expression was less pronounced, but
showed a significant decrease after 72-h stimu-
lation with calcitriol (Fig. 4). This effect was
specific to KLK5 gene expression and did not
affect the genetic expression of other skin-ex-
pressed proteases. This experiment was also
carried out in the RHE system, although only
24-h stimulation with calcitriol was tested,
showing similar inhibition of CAMP gene
expression with topical ivermectin treatment
(Supplementary Table 1). These results provide
clear evidence that ivermectin inhibits KLK5
and LL-37 expression at the gene level, with no
effect on IL-8 gene expression. This effect of
ivermectin was associated with inhibition of
IL-8, IL-6 and CCL2 secretion, suggesting that
ivermectin prevents activation of the inflam-
matory pathways involved in the pathophysi-
ology of rosacea.
DISCUSSION
Augmentation of the cathelicidin innate
immune pathway (specifically KLK5 and LL-37)
has been shown to be a major contributor to the
pathophysiology of rosacea [6, 10]. Agents pre-
venting the production of KLK5 and hCAP18,
and thereby inhibiting the activation of LL-37,
could have a considerable impact on the
inflammation affiliated with rosacea. In the
present study, we demonstrate for the first time
that ivermectin inhibits the expression of KLK5
and the inactive precursor protein of LL-37,
hCAP18, at the gene level in calcitriol-induced
keratinocytes, both in vitro and ex vivo. These
results suggest that ivermectin may act at the
gene level to prevent the activation of inflam-
matory pathways involved in the
pathophysiology of rosacea. Interestingly,
however, previous studies performed with
doxycycline and ivermectin (data not pub-
lished) have demonstrated that ivermectin did
not affect the gene expression of matrix metal-
loproteinases involved in the proteolytic acti-
vation of KLK5.
Earlier studies have shown that facial skin
from patients with rosacea overexpress KLK5
and cathelicidin compared with normal skin
[10]. LL-37 has been shown to be pro-inflam-
matory in several experimental systems [11, 12],
and the current hypothesis is that the aug-
mentation of the cathelicidin immune pathway
is a major contributor to symptoms observed in
rosacea [16]. In light of this, inhibition of
cathelicidin has been suggested to correlate
directly with beneficial therapeutic activity in
patients with rosacea. Indeed, azelaic acid, a
commonly used topical therapy for rosacea, has
been shown to directly inhibit KLK5 and
cathelicidin gene expression [15]. In this study,
the decrease in KLK5 and LL-37 protein
expression observed after pre-treatment with
azelaic acid did not reach statistical significance.
Importantly, however, the levels of KLK5 and
LL-37 expression after ivermectin treatment
were lower than that observed with azelaic acid,
showing increased inhibition (Figs. 1, 3). This
indicates that ivermectin has a greater effect on
the cathelicidin immune pathway than has
been observed with other effective topical
treatments for rosacea.
This inhibition of cathelicidin expression
from keratinocytes correlates well with the
previously reported long-term safety and effi-
cacy of ivermectin treatment. In two 40-week
extension studies assessing the safety and tol-
erability profile of ivermectin versus azelaic acid
in PPR patients over the long term, the iver-
mectin cream 10 mg/g treatment group had a
lower incidence of treatment-related adverse
events compared with the azelaic acid 150 mg/g
treatment group [27]. In addition, ivermectin
has a better long-term tolerability profile com-
pared with azelaic acid. The majority of patients
treated with ivermectin reported no stinging,
dryness or itching, whereas a majority of
patients treated with azelaic acid reported some
of these symptoms [27].
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Fig. 4 Ivermectin treatment inhibits cathelicidin pathway
gene expression in ex vivo human skin biopsies. Ex vivo
skin biopsies were pre-treated with ivermectin at 1% w/v
or vehicle control (100% ethanol) before either 24- or 72-h
topical stimulation with 10 lM calcitriol. Tissues were
lysed and RNA extracted in order to perform qRT-PCR
using pre-developed Taqman Assay probes. a Graphical
representation show fold change modulation of CAMP,
KLK8, KLK7 and KLK5 gene expression after 24-h
stimulation and 72-h stimulation. b Table represents
normalized Ct values considering housekeeping gene
expression (GAPDH, HPRT1 and GUSB) of control
sample (vehicle-treated) at 24 or 72 h. The lower is the
normalized Ct value; the higher is the gene expression
value. Fold induction are calculated for calcitriol-treated
sample using vehicle as reference sample. Data show mean
from three independent experiments. Analyses were per-
formed using Array Studio software. Results were consid-
ered signiﬁcant when at least a twofold difference in
expression level was detected and statistical analysis
revealed an adjusted P value (FDR_BH)\0.05
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The long-term efficacy associated with iver-
mectin was recently demonstrated in an exten-
sion of the Phase III superiority study of
ivermectin versus metronidazole. The results of
this study showed that initial successful treat-
ment with ivermectin cream 10 mg/g signifi-
cantly extended the remission of rosacea
compared with metronidazole cream when
treatment was stopped [28]. The effects of iver-
mectin on KLK5 and CAMP gene expression
ex vivo could explain the increased remission
time seen with ivermectin treatment versus
metronidazole, and this could indicate an
impact of this agent on the course of the dis-
ease. It is important to recognise, however, that
these experiments were conducted in vitro and
ex vivo. Further studies are needed to confirm
these findings in rosacea patients with papulo-
pustular lesions.
CONCLUSIONS
Overall, the results of this study suggest that
ivermectin treatment prevents the augmenta-
tion of the cathelicidin immune pathway,
which has a positive impact on the downstream
inflammatory pathway (e.g., decreased IL-8,
IL-6 and CCL2 secretion). These results suggest
that ivermectin can prevent the inflammatory
effects of rosacea triggered by abnormal LL-37
processing, through the inhibition of KLK5 and
CAMP gene expression in the epidermis.
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